Two AI-native ventures signaled momentum: Latent Labs, founded by former DeepMind team members, emerged with a platform to design drug-like biologics for difficult targets; Phylo raised $13.5 million to launch Biomni Lab, an AI-enabled integrated environment for wet labs. Both companies emphasize agentic AI to accelerate design, execution and analysis in biologics discovery and lab workflows. Latent Labs targets single-step design of therapeutic biologics, promising to shorten discovery timelines for complex targets; Phylo’s platform focuses on operationalizing agentic models to automate experiments, improve reproducibility and compress multi-week workflows into hours. Both moves attract attention from big-name investors and industry partners. These developments underscore the sector’s pivot from pure algorithm claims to integrated, end-to-end AI tools and design platforms that must demonstrate tangible lab-to-clinic impact. Adoption will hinge on reproducible validation, regulatory clarity for AI-designed molecules, and partnerships with established biopharma.